207 related articles for article (PubMed ID: 29615077)
1. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
Crabb S; Danson SJ; Catto JWF; McDowell C; Lowder JN; Caddy J; Dunkley D; Rajaram J; Ellis D; Hill S; Hathorn D; Whitehead A; Kalevras M; Huddart R; Griffiths G
Trials; 2018 Apr; 19(1):216. PubMed ID: 29615077
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
4. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
[TBL] [Abstract][Full Text] [Related]
7. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
8. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
Gross-Goupil M; Domblides C; Lefort F; Ravaud A
Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
[TBL] [Abstract][Full Text] [Related]
10. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Hussain SA; Lester JF; Jackson R; Gornall M; Qureshi M; Elliott A; Crabb SJ; Huddart RA; Vasudev N; Birtle AJ; Worlding J; James ND; Parikh O; Vilarino-Varela M; Alonzi R; Linch MD; Riaz IB; Catto JWF; Powles T; Jones RJ
Lancet Oncol; 2022 May; 23(5):650-658. PubMed ID: 35421369
[TBL] [Abstract][Full Text] [Related]
11. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
12. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
14. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
17. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
19. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
20. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
